Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp53251_8k.htm |
Exhibit 99.1
|
Press Release
www.shire.com
|
 |
Director/PDMR Share Dealings
February 3, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that it was notified today that deferred American Depositary Shares (“ADSs”) granted to Ginger Gregory, a Person Discharging Managerial Responsibilities, were automatically released today in accordance with the terms of a Deferred Share Award granted in February 2014. One ADS is equal to three Ordinary shares of 5 pence each in the Company.
The number of ADSs released and the number that lapsed are as follows:
|
ADSs Released(1)
|
ADSs Lapsed(2)
|
|
2,901
|
1,831
|
|
(1)
|
In accordance with the terms of the Deferred Share Award, the vested deferred ADSs were increased by an amount equivalent, at the date of vesting, to the value of dividends paid by the Company from the date of grant to the date of vesting.
|
|
(2)
|
The number of ADSs lapsed is equivalent in value to Ms. Gregory’s tax liability resulting from the release of the deferred ADSs.
|
|
(3)
|
No amount was payable by Ms. Gregory on release.
|
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX